Brad Ebel

Brad Ebel possesses extensive experience in the biopharmaceutical industry, currently serving in multiple roles at CRISPR Therapeutics since September 2019, including Site Head of Internal Manufacturing and Interim Head of Quality Control. Prior to CRISPR Therapeutics, Brad held the position of Director-Head of Operations and Systems at Takeda and Director-Head of Operations and Systems at Shire, overseeing critical departments supporting Process Development Technical Services. Brad's earlier experience includes significant roles at Globeimmune, where responsibilities included project management and establishing cGMP labs, and at Baxter Hemoglobin Therapeutics, where contributions involved producing clinical trial materials. Brad earned a Bachelor of Science degree in Chemistry from Westminster College (PA) in 2001.